UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000033387
Receipt number R000038067
Scientific Title Evaluation of glucagon secretion in type 2 diabetes
Date of disclosure of the study information 2018/07/13
Last modified on 2021/04/12 20:09:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of glucagon secretion in type 2 diabetes

Acronym

Type 2 diabetes and glucagon

Scientific Title

Evaluation of glucagon secretion in type 2 diabetes

Scientific Title:Acronym

Type 2 diabetes and glucagon

Region

Japan


Condition

Condition

Type 2 diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Evaluation of paradoxical secretion of glucagon in patients with type 2 diabetes

Basic objectives2

Bio-availability

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Evaluation of glucagon secretion when administered diet

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

12 years-old <=

Age-upper limit

100 years-old >=

Gender

Male and Female

Key inclusion criteria

Diagnosed type 2 diabetes by diabetologists.

Key exclusion criteria

Patients uncontrolled fasting glucose at 80-180 mg/dL.
Patients with cerebrovascular disease and/or cardiovascular disease.
Pregnant women.
Lactating women.

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Ichiro
Middle name
Last name Horie

Organization

Nagasaki University Hospital

Division name

Endocrinology and Metabolism

Zip code

852-8501

Address

1-7-1 Sakamoto, Nagasaki, Japan

TEL

0958197200

Email

holy197741@me.com


Public contact

Name of contact person

1st name Ichiro
Middle name
Last name Horie

Organization

Nagasaki University Hospital

Division name

Endocrinology and Metabolism

Zip code

852-8501

Address

1-7-1 Sakamoto, Nagasaki, Japan

TEL

0958197200

Homepage URL


Email

holy197741@me.com


Sponsor or person

Institute

Nagasaki University Hospital

Institute

Department

Personal name



Funding Source

Organization

Self funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Nagasaki University Hospital Clinical Study Review Board

Address

1-7-1 Sakamoto, Nagasaki

Tel

095-819-7200

Email

holy197741@me.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2018 Year 07 Month 13 Day


Related information

URL releasing protocol

https://pubmed.ncbi.nlm.nih.gov/33369175/

Publication of results

Published


Result

URL related to results and publications

https://pubmed.ncbi.nlm.nih.gov/33369175/

Number of participants that the trial has enrolled

23

Results

The levels of plasma glucagon were elevated and peaked 30 min after the mixed meal ingestion in both type 1 diabetes and type 2 diabetes patients.

Results date posted

2021 Year 04 Month 12 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Controlling postprandial glucose levels in patients with type 1 diabetes is challenging even under the adequate treatment of insulin injection. Recent studies showed that dysregulated glucagon secretion exacerbates hyperglycemia in type 2 diabetes patients, but little is known in type 1 diabetes patients. We investigated whether the glucagon response to a meal ingestion could influence the postprandial glucose excursion in patients with type 1 diabetes.

Participant flow

We enrolled 34 patients with type 1 diabetes and 23 patients with type 2 diabetes as controls.

Adverse events

None

Outcome measures

All patients underwent a liquid mixed meal tolerance test. We measured levels of plasma glucose, C-peptide and glucagon at fasting (0 min), and 30, 60 and 120 min after meal ingestion. All type 1 diabetes patients received their usual basal insulin and two-thirds of the necessary dose of the premeal bolus insulin.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 06 Month 01 Day

Date of IRB

2018 Year 07 Month 10 Day

Anticipated trial start date

2018 Year 07 Month 17 Day

Last follow-up date

2020 Year 04 Month 01 Day

Date of closure to data entry

2020 Year 04 Month 01 Day

Date trial data considered complete

2020 Year 08 Month 01 Day

Date analysis concluded

2020 Year 10 Month 01 Day


Other

Other related information

1. Taking a 200ml of CalorieMate at fasting.
2. Blood sampling at 0, 30, 60, 90, 120 min after administration of CalorieMate.
3. Measure plasma glucose, insulin, C-peptide and glucagon in each sample.


Management information

Registered date

2018 Year 07 Month 13 Day

Last modified on

2021 Year 04 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000038067


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name